Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists

In patients with type 2 diabetes and stage 4-5 chronic kidney disease, initiating an SGLT2i, relative to a GLP-1 RA, was associated with a lower risk of adverse kidney events and comparable cardiovascular and mortality risks. Further studies are warranted to confirm these findings.